Oestrogen-regulated genes in breast cancer and endocrine therapy response
Author Information
Author(s): RA McClelland, DL Manning, JMW Gee, P Willsher, JFR Robertson, 10 Ellis, RW Blamey, RI Nicholson
Primary Institution: Tenovus Cancer Research Centre, University Hospital of Wales
Hypothesis
The study evaluates the significance of expression of the oestrogen-inducible pLIV1 and pS2 mRNAs in predicting endocrine responsiveness in recurrent breast cancer.
Conclusion
The expression of pLIV1 and pS2 mRNAs is significantly associated with the outcome of first-line endocrine therapy, but the predictive capability is not absolute.
Supporting Evidence
- Significant associations were observed between pLIV1/ER and pS2/ER status.
- Positive pLIV1, pS2, and ER statuses were predictive of endocrine responsiveness.
- Most responders to therapy were pLIV1 positive, while non-responders were often pLIV1 negative.
Takeaway
This study looked at how certain genes in breast cancer can help doctors predict if a treatment will work, but it's not always reliable.
Methodology
Northern hybridization analyses of oestrogen-inducible mRNAs were compared with oestrogen receptor assessments in breast tumours.
Limitations
The predictive capability of pLIV1 and pS2 expression was not absolute, with some positive cases not responding to therapy.
Participant Demographics
14 premenopausal (mean age 44 years) and 26 postmenopausal (mean age 67 years) patients.
Statistical Information
P-Value
P < 0.03 for pLIV1, P < 0.001 for pS2, P < 0.004 for ERICA
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website